Acrivon Therapeutics, Inc. Statistics
Want to see ACRV full AI Analyst Report?
Acrivon Therapeutics, Inc. (ACRV) Stock Statistics & Valuation Metrics
Total Valuation
Acrivon Therapeutics, Inc. has a market cap or net worth of $62.14M. The enterprise value is -$13.37M.
- Market Cap
- $62.14M
- Enterprise Value
- -$13.37M
Share Statistics
Acrivon Therapeutics, Inc. has 42,853,363 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 42,853,363
- Owned by Insiders
- 35.81%
- Owned by Institutions
- 12.63%
Financial Efficiency
Acrivon Therapeutics, Inc.’s return on equity (ROE) is -0.69 and return on invested capital (ROIC) is -73.00%.
- Return on Equity (ROE)
- -0.69
- Return on Assets (ROA)
- -0.60
- Return on Invested Capital (ROIC)
- -73.00%
- Return on Capital Employed (ROCE)
- -0.74
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.04M
- Employee Count
- 75
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Acrivon Therapeutics, Inc. is -0.77. Acrivon Therapeutics, Inc.’s PEG ratio is -0.04.
- PE Ratio
- -0.77
- PS Ratio
- 0.00
- PB Ratio
- 0.70
- Price to FCF
- -0.97
- Price to Operating Cash Flow
- -0.96
- PEG Ratio
- -0.04
Income Statement
In the last 12 months, Acrivon Therapeutics, Inc. had revenue of 0 and earned -77.91M in profits. Earnings per share was -2.02.
- Revenue
- 0
- Gross Profit
- -1.36M
- Operating Income
- -84.11M
- Pretax Income
- -77.91M
- Net Income
- -77.91M
- EBITDA
- -76.55M
- Earnings Per Share (EPS)
- -2.02
Cash Flow
In the last 12 months, operating cash flow was -62.92M and capital expenditures -1.22M, giving a free cash flow of -64.14M billion.
- Operating Cash Flow
- -62.92M
- Free Cash Flow
- -64.14M
- Free Cash Flow per Share
- -1.53
Dividends & Yields
Acrivon Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -103.22%
- Earnings Yield
- -122.34%
Stock Price Statistics
- Beta
- 1.75
- 52-Week Price Change
- -29.95%
- 50-Day Moving Average
- 1.84
- 200-Day Moving Average
- 1.75
- Relative Strength Index (RSI)
- 32.72
- Average Volume (3m)
- 281.82K
Important Dates
Acrivon Therapeutics, Inc. upcoming earnings date is Apr 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 12, 2026
- Next Earnings Date
- Apr 01, 2027
- Ex-Dividend Date
- ―
Financial Position
Acrivon Therapeutics, Inc. as a current ratio of 7.69, with Debt / Equity ratio of 2.41%
- Current Ratio
- 7.69
- Quick Ratio
- 7.69
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.51
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Acrivon Therapeutics, Inc. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Acrivon Therapeutics, Inc. EV to EBITDA ratio is -0.29, with an EV/FCF ratio of -0.36.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.29
- EV to Free Cash Flow
- -0.36
- EV to Operating Cash Flow
- -0.36
Balance Sheet
Acrivon Therapeutics, Inc. has $89.96M in cash and marketable securities with $2.12M in debt, giving a net cash position of $87.84M billion.
- Cash & Marketable Securities
- $89.96M
- Total Debt
- $2.12M
- Net Cash
- $87.84M
- Net Cash Per Share
- $2.05
- Tangible Book Value Per Share
- $2.07
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Acrivon Therapeutics, Inc. is $7.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $7.50
- Price Target Upside
- 417.24% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 16.04%
Scores
- Smart Score
- 5
- AI Score
- 47
